Loading
Extracellular Vesicles in Disease / Nanoplatforms for Cancer Theranostics / Immune Cells in Cancer · Journal article
Frontiers in Immunology · September 7, 2026
Raises a question worth testing. It does not answer one.
This narrative review examines immune cell-derived exosomes as bidirectional regulators in the tumor microenvironment, cataloguing reported antitumor mechanisms (antigen presentation, T-cell activation, macrophage reprogramming, checkpoint modulation) and protumor mechanisms (immune suppression, metastasis promotion, treatment resistance). The evidence remains mechanistic and heterogeneous, with clinical translation limited by characterization inconsistency and manufacturing challenges rather than demonstrated clinical benefit or harm.
Narrative review.
Antitumor exosomes can enhance antigen presentation, activate natural killer cell and T-cell responses, and suppress tumor growth and metastasis. Exosomes from Tregs, MDSCs, and TAMs promote immune suppression, checkpoint-mediated immune escape, invasion, metastasis, and treatment resistance. Biological effects are influenced by immune-cell source, activation state, vesicular cargo, recipient-cell type, and tumor context.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a narrative review synthesizing mechanistic literature on immune cell-derived exosomes in cancer, raising questions about bidirectional regulation rather than reporting new empirical data or clinical outcomes.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Immune cell-derived exosomes are important mediators of intercellular communication within the tumor microenvironment. Their biological effects are influenced by the immune-cell source and activation state, vesicular cargo, recipient-cell type, and tumor context. This review examines immune cell-derived exosomes as bidirectional regulators of cancer-associated signaling, with emphasis on their antitumor and protumor mechanisms rather than classification by parent cell type alone. Antitumor exosomes can enhance antigen presentation, activate natural killer cell and T-cell responses, reprogram tumor-associated macrophages, reduce immune-checkpoint signaling, induce tumor-cell death, and suppress tumor growth and metastasis. Conversely, exosomes released by regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and other immune populations may promote immune suppression, tolerogenic reprogramming, checkpoint-mediated immune escape, invasion, metastasis, and treatment resistance. These effects are mediated through the transfer of proteins, receptors, enzymes, cytokine-related molecules, microRNAs, long non-coding RNAs, and other regulatory cargo that modulate signaling networks such as NF-κB, MAPK/ERK, PI3K-AKT-mTOR, STAT3, PD-1/PD-L1, apoptotic, and β-catenin/HIF-1α-associated pathways. Despite their therapeutic and diagnostic potential, clinical translation remains limited by extracellular-vesicle heterogeneity, incomplete identification of functional cargo, inconsistent isolation and characterization methods, manufacturing challenges, storage instability, and difficulties in tracking vesicles in vivo. Future studies should aim to define the relationships among parent-cell state, exosomal cargo, recipient-cell identity, and downstream biological responses. Additionally, integrating experimental data with computational and artificial-intelligence-based approaches may support single-vesicle classification, inference of EV cellular origin, and the development of more reproducible exosome-based cancer therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.